|Bid||80.00 x 800|
|Ask||82.00 x 1100|
|Day's range||80.29 - 82.17|
|52-week range||60.08 - 107.44|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||39.60|
|Earnings date||26 Feb. 2019 - 4 Mar. 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||104.24|
After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.
On a per-share basis, the Beijing-based company said it had profit of 83 cents. Earnings, adjusted for non-recurring costs, were $1.17 per share. The biopharmaceutical company posted revenue of $120.4 ...
Ping An Insurance (Group) Co., China’s largest insurer by market value, is considering a rival offer for plasma treatment provider China Biologic Products Holdings Inc., people familiar with the matter said. An arm of Ping An is in talks with other investors about a potential joint bid for Beijing-based China Biologic, according to the people, who asked not to be identified because the information is private. Any offer would be higher than the $110-per-share proposal from Chinese buyout firm Citic Capital, which valued U.S.-listed China Biologic at about $3.6 billion, the people said.
Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.
Assessing China Biologic Products Holdings Inc’s (NASDAQ:CBPO) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple senseRead More...